Blog Category:

Strategies to Close Gaps in Herpes Zoster Vaccination

Despite the availability of a safe and effective recombinant zoster vaccine (RZV) for herpes zoster (HZ), vaccination uptake and series completion remain insufficient, leaving many at-risk individuals—particularly older adults, immunocompromised patients, and underserved populations—vulnerable to preventable disease and its impact …

A CaseWise™ Webcast – CIDP in Focus: Advancing Precision Across the Patient Journey from Early Recognition to Downstream Management

 What if the neuropathy in front of you isn’t what it seems? Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common immune-mediated peripheral neuropathy, yet it remains widely underrecognized. Because its symptoms mimic other neuropathies, CIDP is too often misdiagnosed …

Red Flags to Renal Rescue: Strengthening LN Care in Federal and FQHC Practice Environments

Lupus nephritis (LN) is one of the most consequential organ manifestations of systemic lupus erythematosus (SLE), occurring in approximately 40% to 60% of patients, most often within the first 5 years of diagnosis, and progressing to end-stage kidney disease in …

Livestream: Beyond the Bowel: Addressing Obesity as a Modifiable Driver of IBD Outcomes

Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …

Beyond the Bowel: Addressing Obesity as a Modifiable Driver of IBD Outcomes

Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …

Extraintestinal Manifestations in IBD — Screening, Referral Triggers, and Multidisciplinary Care Pathways

Extraintestinal manifestations (EIMs) affect up to one-third of patients with inflammatory bowel disease (IBD) and can significantly contribute to morbidity, impaired quality of life, and long-term disease burden, yet they remain inconsistently recognized and managed in clinical practice. Many gastroenterologists …

Beyond Symptoms — The Hidden Burden of IBD and the Future of Disease Modification

Although treatment advances in inflammatory bowel disease (IBD) have improved symptom control, many patients continue to experience progressive structural bowel damage and systemic complications that are not adequately addressed in routine care. Gastroenterologists and multidisciplinary gastrointestinal (GI) care teams often …

Findings from Phase 2 of a Health Equity Educational Initiative Addressing Racial Disparities and Bias

Systemic health inequities disproportionately impact underserved racial and ethnic populations, leading to higher morbidity, mortality, and reduced quality of life. Socioeconomic disadvantages, racial bias, and barriers to care contribute to these disparities, yet they often go unnoticed by health care …

From Trial to Treatment: Using Modern Evidence, Expert Insight, and Practice Simulation to Navigate the Integration of Bispecific Antibodies into the Care of Patients with Multiple Myeloma

The rapidly evolving multiple myeloma (MM) treatment landscape has created unprecedented opportunities, while introducing new complexities for clinicians caring for patients with relapsed/refractory (R/R) disease. In just a few years, bispecific antibodies (BsAbs) have emerged as highly effective treatment options, …